POSITRON EMISSION TOMOGRAPHY DEMONSTRATES DOPAMINE-D2 RECEPTOR SUPERSENSITIVITY IN THE STRIATUM OF PATIENTS WITH EARLY PARKINSONS-DISEASE

被引：160

作者：

RINNE, UK

LAIHINEN, A

RINNE, JO

NAGREN, K

BERGMAN, J

RUOTSALAINEN, U

机构：

[1] Department of Neurology, University of Turku, Turku

[2] Cyclotron Laboratory, University of Turku, Turku

[3] Pet Laboratory, University Hospital of Turku, Turku

来源：

MOVEMENT DISORDERS | 1990年 / 5卷 / 01期

关键词：

D[!sub]2[!/sub] receptors; Dopamine; Parkinson's disease; Positron emission tomography; Raclopride;

D O I：

10.1002/mds.870050114

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Striatal dopamine D2 receptor binding was studied in vivo with positron emission tomography in seven patients with early Parkinson's disease using [11C]–raclopride. The patients had unilateral symptoms and none of them had received levodopa treatment. The accumulation of [11C]–raclopride in the striatum was rapid and reached a steady state at approximately 40 min after injection. The binding of [11C]–raclopride was measured in the striatum and cerebellum: The total striatal radioactivity in both hemispheres was counted and the respective striatum/cerebellum ratios were calculated. The striatum/cerebellum ratio of [11C]–raclopride binding was significantly (p < 0.01) increased in the hemisphere contralateral to the parkinsonian symptoms as compared with the opposite hemisphere. Thus, this study demonstrates that there is denervation supersensitivity in dopamine D2 receptor binding in early Parkinson's disease. Copyright © 1990 Movement Disorder Society

引用

页码：55 / 59

页数：5

共 23 条

[1]

Garnett ES, Nahmias C, Firnau G., Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography, Can J Neurol Sci, 11, pp. 174-179, (1984)

[2]

Nahmias C, Garnett ES, Firnau G, Lang A., Striatal dopamine distribution in parkinsonian patients during life, J Neurol Sci, 69, pp. 223-230, (1985)

[3]

Leenders KL, Palmer AJ, Quinn N, Et al., Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography, J Neurol Neurosurg Psychiatry, 49, pp. 853-860, (1986)

[4]

Martin WRW, Adam MJ, Bergstrom M, Et al., In vivo study of DOPA metabolism in Parkinson's disease, Recent developments in Parkinson's disease, pp. 97-102, (1986)

[5]

Tedroff J, Aquilonius S-M, Hartvig P, Et al., Monoamine re‐uptake sites in the human brain evaluated in vivo by means of 11C‐nomifensine and positron emission tomography: the effects of age and Parkinson's disease, Acta Neurol Scand, 77, pp. 192-201, (1988)

[6]

Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O., Receptor basis for dopaminergic supersensitivity in Parkinson's disease, Nature, 273, pp. 59-61, (1978)

[7]

Rinne UK, Koskinen V, Lonnberg P., Dopamine receptors in the parkinsonian brain, J Neural Transm, 51, pp. 97-106, (1981)

[8]

Guttman M, Seeman P., L‐Dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum, J Neural Transm, 64, pp. 93-103, (1985)

[9]

Bokobza B, Ruberg M, Scatton F, Javoy-Agid F, Agid Y., 3H‐spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy, Eur J Pharmacol, 99, pp. 167-175, (1984)

[10]

Pierot L, Desnos C, Blin J, Et al., D1 and D2–type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy, J Neurol Sci, 86, pp. 291-306, (1988)

← 1 2 3 →